Clinical Molecular Testing Remains a Phenomenon of the Developed World, According to Kalorama Information
12 Feb 2013 • by Natalie Aster
The first generation of molecular testing tools includes basic, time consuming and labor intensive techniques such as the Southern blot, DNA probes, pulsed field gel electrophoresis and capillary electrophoresis. The new report "World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas)" by Kalorama Information states that these techniques are still used however their influence in the evolution of molecular testing has been overshadowed by the power of PCR and other amplification techniques, sequencing, mass spectroscopy, microarrays and biochips.
World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas)
Published: January, 2013
Price: US$ 4,500.00
We now are in the full evolution of the third generation of molecular testing or the “next generation” of a number of molecular test solutions. These have had several common effects on molecular diagnostics that are leading to a further expansion of clinical lab testing possibilities:
Reduced test time to hours versus days
More test data leads to a better understanding of disease processes
Easier to use and thus found in more clinical labs
Automated sample to answer test procedures
A variety instrument choices – from high throughput systems to table top low volume options
Data analysis algorithms incorporated in testing system
This market estimate covers market authorized assays and reagents. In-lab developed tests, which account for a large portion of this IVD segment is not included. It is beyond the scope of this report to estimate the market for these in-lab developed tests. However, with the increased market penetration of molecular assays, demand will decrease the cost of commercialized kits and the need for standardization will make commercial kits more attractive, especially for small labs.
Overall, clinical molecular testing remains a phenomenon of the developed world. At least 80% of the molecular assays performed are concentrated in the developed world—North America and Western Europe. Recently molecular test companies and laboratories have established partnerships in the top seven emerging markets: Brazil, Russia, India, China, South Korea, Mexico and Turkey. As market growth in the U.S. has started to reach a steady state of some 5% annual growth, these emerging markets offer opportunities for growth and market expansion.
More information can be found in the report “World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas)” by Kalorama Information.
To order the report or ask for sample pages contact [email protected]